EcoDrugPlus

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSUAMG00000010867
Gene Symbol: MAPK1
2 Cross references
213 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSUAMG00000017893
Gene Symbol: MAPK10
2 Cross references
147 Possible Orthologues:

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSUAMG00000013511
Gene Symbol: MAPK11
2 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSUAMG00000024685
Gene Symbol: MAPK14
2 Cross references
280 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSUAMG00000024157
Gene Symbol: MAPK3
2 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSUAMG00000006046
Gene Symbol: MAPK8
2 Cross references
294 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSUAMG00000021882
Gene Symbol: MAPK9
2 Cross references
219 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSUAMG00000022381
Gene Symbol: MAP2K2
1 Cross references
263 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSUAMG00000022993
Gene Symbol: MAP3K1
2 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSUAMG00000028438
Gene Symbol: MAP3K10
2 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSUAMG00000020824
Gene Symbol: MAP3K11
2 Cross references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSUAMG00000023891
Gene Symbol: MAP3K12
2 Cross references
254 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).